Senti Biosciences, Inc. SEC 10-Q Report
Nov 13, 2025, 17:13 GMT-52 min read
 SNTI-5.29%
Senti Biosciences, Inc., a biotechnology company focused on developing gene circuit technologies for next-generation cell and gene therapies, has released its Form 10-Q report for the third quarter of 2025. The report provides a comprehensive overview of the company's financial performance and operational advancements, reflecting its ongoing efforts to create smarter medicines for complex diseases.
Financial Highlights
Net Loss: $18.1 million for the three months ended September 30, 2025, compared to $28.9 million for the same period in 2024, reflecting a decrease in losses.
Net Loss: $47.0 million for the nine months ended September 30, 2025, compared to $52.2 million for the same period in 2024, indicating a reduction in losses.
Basic and Diluted Net Loss Per Share: $0.69 for the three months ended September 30, 2025, compared to $6.31 for the same period in 2024, showing a significant improvement.
Basic and Diluted Net Loss Per Share: $2.25 for the nine months ended September 30, 2025, compared to $11.41 for the same period in 2024, demonstrating a substantial decrease in loss per share.
Business Highlights
Gene Circuit Platform Development: Senti Biosciences is advancing its gene circuit platform technologies, which are designed to program next-generation cell and gene therapies with biological logic to sense inputs, compute decisions, and respond to cellular environments. This platform is central to the company's mission to create smarter medicines for complex diseases.
Clinical Trials and Product Candidates: The company is actively developing a pipeline of medicines using chimeric antigen receptor (CAR) white blood cells. Key product candidates include SENTI-202 for blood cancers, which is in a Phase 1 clinical trial, and SENTI-301A for solid tumors, which has faced challenges due to dose-limiting toxicities.
SENTI-202 Clinical Progress: SENTI-202, an off-the-shelf Logic Gated selective CD33 OR FLT3 NOT EMCN CAR-NK investigational cell therapy, has received Orphan Drug Designation from the FDA for treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia. The recommended Phase 2 dose has been determined, and enrollment is ongoing.
Operational Challenges with GeneFab: GeneFab, a related party, is in default under its sublease with Senti Biosciences, owing $4.7 million in past-due rent payments. This has impacted Senti's operations, as the Alameda lease obligations are expected to be funded by these sublease payments.
Manufacturing and Research Services: Senti has prepaid future manufacturing and research services with GeneFab, which supports the clinical manufacturing of its CAR-NK programs. The company is utilizing these services to advance its product candidates.
Board and Management Changes: The company has seen significant changes in its board and management, including the appointment of a new Chief Financial Officer, Jay Cross, and the addition of new board members, Feng Hsiung and Bryan Baum, to support its strategic direction.
Future Outlook: Senti anticipates increased expenses and operating losses as it continues to advance its gene circuit platform, expand clinical trials, and enhance its manufacturing capabilities. The company is focused on addressing operational challenges and advancing its pipeline to achieve long-term growth.
SEC Filing: Senti Biosciences, Inc. [ SNTI ] - 10-Q - Nov. 13, 2025 |
